MX2024009216A - Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. - Google Patents
Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.Info
- Publication number
- MX2024009216A MX2024009216A MX2024009216A MX2024009216A MX2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A MX 2024009216 A MX2024009216 A MX 2024009216A
- Authority
- MX
- Mexico
- Prior art keywords
- enpp1
- inhibitors
- phosphodiesterase
- ectonucleotide pyrophosphatase
- ectonucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022074739 | 2022-01-28 | ||
| CN2022140318 | 2022-12-20 | ||
| PCT/CN2023/073579 WO2023143520A1 (en) | 2022-01-28 | 2023-01-28 | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009216A true MX2024009216A (es) | 2024-08-06 |
Family
ID=87470622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009216A MX2024009216A (es) | 2022-01-28 | 2023-01-28 | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250101019A1 (https=) |
| EP (1) | EP4469456A4 (https=) |
| JP (1) | JP2025502943A (https=) |
| KR (1) | KR20240142481A (https=) |
| CN (1) | CN118871439A (https=) |
| AR (1) | AR128383A1 (https=) |
| AU (1) | AU2023213905A1 (https=) |
| CA (1) | CA3247162A1 (https=) |
| IL (1) | IL313821A (https=) |
| MX (1) | MX2024009216A (https=) |
| TW (1) | TW202340190A (https=) |
| WO (1) | WO2023143520A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024074128A1 (en) * | 2022-10-08 | 2024-04-11 | Insilico Medicine Ip Limited | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| CN121793967A (zh) * | 2023-07-06 | 2026-04-03 | 英矽智能科技知识产权有限公司 | 外切核苷酸焦磷酸酶/磷酸二酯酶1 (enpp1)抑制剂组合及其用途 |
| WO2025026383A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| WO2025026377A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE912874A1 (en) * | 1990-08-15 | 1992-02-26 | British Bio Technology | Compounds |
| GB9200209D0 (en) * | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US6489338B2 (en) * | 2000-06-13 | 2002-12-03 | Bristol-Myers Squibb Company | Imidazopyridine and imidazopyrimidine antiviral agents |
| KR101142363B1 (ko) * | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| EP2099796B1 (en) * | 2006-11-30 | 2011-06-01 | Genentech, Inc. | Aza-indolyl compounds and methods of use |
| WO2015038417A1 (en) * | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
| CN111615388B (zh) * | 2017-07-27 | 2023-11-14 | 斯汀格瑞治疗股份有限公司 | 癌症免疫治疗剂 |
| CN111732584B (zh) * | 2019-03-25 | 2024-02-27 | 复旦大学 | 二芳基取代稠杂环类化合物及其制备方法和在制药中的用途 |
| JP7598875B2 (ja) * | 2019-04-12 | 2024-12-12 | リボサイエンス リミティド ライアビリティ カンパニー | エクトヌクレオチドピロホスファターゼホスホジエステラーゼ１阻害剤としての二環式ヘテロアリール誘導体 |
| CN115151253B (zh) * | 2019-09-23 | 2025-04-15 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| CA3291973A1 (en) * | 2021-01-29 | 2026-03-02 | Txinno Bioscience Inc. | Benzotriazole Derivative Having Inhibitory Activity Against Ectonucleotide Pyrophosphatase-Phosphodiesterase, and Use Thereof |
-
2023
- 2023-01-28 CN CN202380026751.8A patent/CN118871439A/zh active Pending
- 2023-01-28 JP JP2024539810A patent/JP2025502943A/ja active Pending
- 2023-01-28 WO PCT/CN2023/073579 patent/WO2023143520A1/en not_active Ceased
- 2023-01-28 US US18/832,564 patent/US20250101019A1/en active Pending
- 2023-01-28 IL IL313821A patent/IL313821A/en unknown
- 2023-01-28 EP EP23746397.1A patent/EP4469456A4/en active Pending
- 2023-01-28 MX MX2024009216A patent/MX2024009216A/es unknown
- 2023-01-28 KR KR1020247028329A patent/KR20240142481A/ko active Pending
- 2023-01-28 AU AU2023213905A patent/AU2023213905A1/en active Pending
- 2023-01-28 CA CA3247162A patent/CA3247162A1/en active Pending
- 2023-01-30 TW TW112102960A patent/TW202340190A/zh unknown
- 2023-01-30 AR ARP230100212A patent/AR128383A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL313821A (en) | 2024-08-01 |
| US20250101019A1 (en) | 2025-03-27 |
| EP4469456A4 (en) | 2025-12-31 |
| CN118871439A (zh) | 2024-10-29 |
| KR20240142481A (ko) | 2024-09-30 |
| AU2023213905A1 (en) | 2024-07-11 |
| CA3247162A1 (en) | 2023-08-03 |
| WO2023143520A1 (en) | 2023-08-03 |
| AR128383A1 (es) | 2024-04-24 |
| EP4469456A1 (en) | 2024-12-04 |
| TW202340190A (zh) | 2023-10-16 |
| JP2025502943A (ja) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005839A (es) | Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos. | |
| MX2024009216A (es) | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| MX2025008092A (es) | Inhibidores de kif18a y usos de los mismos | |
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| MX2024003922A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos. | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| MX2021005924A (es) | Compuestos y metodos de uso de los mismos para el tratamiento del cancer. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
| MX2022011697A (es) | Inhibidores de ciclofilina y usos de los mismos. | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2025003515A (es) | Moduladores de akt1 | |
| SA523440403B1 (ar) | Magl مثبط | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| MX2025000151A (es) | Agonistas de trpml1 con oxazol y usos de los mismos | |
| WO2024099364A3 (en) | Fused multicyclic compounds and their use as parp1 inhibitors | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| MX2025012370A (es) | Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta | |
| MX2025001493A (es) | Inhibidores de cinasa dependiente de ciclina (cdk) 12 y/o cdk13 y usos de los mismos | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| MX2025011086A (es) | Inhibidores de inflamasoma nlrp3 y usos de los mismos | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| AR121477A1 (es) | Compuestos y métodos para el tratamiento de infecciones fúngicas | |
| MX2024003859A (es) | Inhibidores de lpxc y usos de estos. |